AbbVie (NYSE:ABBV), a dividend-paying pharmaceutical company best known for its blockbuster drug Humira, is closing in on its first-year anniversary. After being spun off from Abbott Labs at the start of 2013, many investors questioned the company's future given Humira's 2016 patent expiration date. However, there are a number of signs that it does, in fact, have many opportunities to grow.
In the following video, analyst Max Macaluso breaks down three of AbbVie's biggest opportunities, including its experimental hepatitis C treatment, expanding Humira's label, and its partnerships with smaller biotech companies.
9 rock-solid dividend stocks to watch
Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.